Iterum Therapeutics Files Proxy Materials

TL;DR

Iterum Therapeutics filed proxy docs, likely for a shareholder vote. Stay tuned.

AI Summary

Iterum Therapeutics plc filed a Definitive Additional Materials proxy statement on September 11, 2024. This filing relates to the company's solicitation of proxies from its shareholders. The specific purpose of this solicitation is not detailed in the provided excerpt, but it is a standard regulatory filing for shareholder meetings or votes.

Why It Matters

This filing indicates that Iterum Therapeutics is actively engaging with its shareholders regarding corporate matters, which could involve significant decisions affecting the company's future direction or governance.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEFA14A) and does not inherently present new risks to investors based on the provided text.

Key Players & Entities

• Iterum Therapeutics plc (company) — Registrant filing the proxy statement
• 0000950170-24-105561 (filing_id) — Accession number for the SEC filing
• 20240911 (date) — Date of filing

FAQ

Filing Documents

• itrm_proxy_letter_shareh.htm (DEFA14A) — 32KB
• img109358456_0.jpg (GRAPHIC) — 3KB
• 0000950170-24-105561.txt ( ) — 37KB

From the Filing

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a-12 Iterum Therapeutics plc (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 [The following communication was sent or made available commencing on September 11, 2024 to certain shareholders of Iterum Therapeutics plc] September 11, 2024 Dear Shareholder,  We are writing to you in connection with the upcoming extraordinary meeting of shareholders which has been adjourned until 23 September 2024 (the “EGM”). Now, more than ever before, the vote at the upcoming EGM is critical to the future of Iterum Therapeutics. We continue to focus on a strategic process to sell, license, or otherwise dispose of our rights to sulopenem with the goal of maximizing stakeholder value and have engaged a financial advisor to assist management and the board in evaluating strategic alternatives. Such process can be costly and time consuming. In the meantime, having the flexibility to raise additional capital through the issue of new shares for cash will help ensure we can continue to fund our strategic process with the goal of maximising stakeholder value and ensure the advancement of oral sulopenem, a much needed treatment option. YOUR VOTE IS EXTREMELY IMPORTANT • If we do not have the ability to raise additional capital, including through the issuance of shares for cash, to fund our operating expenses beyond January 2025 including repayment of the 6.500% exchangeable senior subordinated notes due January 2024 (the “Exchangeable Notes”), we will be severely limited in our ability to continue as a going concern and subject to major insolvency risk which may result in the bankruptcy, reorganization and/or the break-up of the Company which in turn would most likely lead to a significant destruction of shareholder value , including dilution or even an elimination of shareholders’ interests in the Company. • Even with the recently completed Rights Offering in August, we currently have insufficient funds to repay the Exchangeable Notes. We require additional capital to repay the Exchangeable Notes and continue to fund the business . • Our ability to raise additional capital through the issue of new shares for cash, even in another pro-rata rights offering, is severely limited without the disapplication of pre-emption rights. • Having the flexibility to raise additional capital through the issue of new shares for cash will help ensure we can continue to fund our strategic process . • We may become subject to delisting from Nasdaq Capital Market if we are unable to regain compliance with Nasdaq Listing Rule 5550(b)(1) by raising additional equity capital efficiently. REMEMBER: Your vote is important, no matter how large or small your holdings may be. Please take a moment to vote your shares “FOR” the pre-emption proposal set out in the proxy. Even if you have voted against the proposal previously, you may change your vote and revoke your proxy prior to the EGM by following the instructions set out in the proxy. If you have previously submitted your proxy or otherwise voted on the proposal at the EGM and do not wish to change your vote, you need not take any action. Sincerely,  ________________________ Corey N. Fishman President and Chief Executive Officer

View Full Filing

View this DEFA14A filing on SEC EDGAR